Oncternal Therapeutics マネジメント

マネジメント基準チェック /34

Oncternal Therapeuticsの CEO はJim Breitmeyerで、 Jun2019年に任命され、の在任期間は 5.42年です。の年間総報酬は$ 1.62Mで、 37.5%給与と62.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.11%を直接所有しており、その価値は$ 23.28K 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と5.4年です。

主要情報

Jim Breitmeyer

最高経営責任者

US$1.6m

報酬総額

CEO給与比率	37.5%
CEO在任期間	5.4yrs
CEOの所有権	1.1%
経営陣の平均在職期間	3.8yrs
取締役会の平均在任期間	5.4yrs

経営陣の近況

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Jun 14

Recent updates

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Jun 14

Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Mar 03

Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Nov 06

Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

Jul 12

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Jan 12

FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oct 03

Oncternal Therapeutics begins phase 3 study of zilovertamab

Sep 27

Oncternal Therapeutics: Selling For Under Cash Value

Sep 02

Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M

Aug 09

Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Aug 07

Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Nov 09

Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company

Oct 10

Oncternal: Solid Data In 2 Cancers With High Unmet Need

Jun 17

We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

May 05

CEO報酬分析

Oncternal Therapeutics の収益と比較して、Jim Breitmeyer の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$35m
Jun 30 2024	n/a	n/a	-US$36m
Mar 31 2024	n/a	n/a	-US$36m
Dec 31 2023	US$2m	US$609k	-US$39m
Sep 30 2023	n/a	n/a	-US$42m
Jun 30 2023	n/a	n/a	-US$43m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$2m	US$580k	-US$44m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$39m
Mar 31 2022	n/a	n/a	-US$35m
Dec 31 2021	US$5m	US$557k	-US$31m
Sep 30 2021	n/a	n/a	-US$26m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$18m
Dec 31 2020	US$780k	US$530k	-US$17m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$37m
Dec 31 2019	US$1m	US$502k	-US$34m
Sep 30 2019	n/a	n/a	-US$31m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$518k	US$426k	-US$7m

報酬と市場: Jimの総報酬 ($USD 1.62M ) は、 US市場 ($USD 647.72K ) の同規模の企業の平均を上回っています。

報酬と収益: Jimの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jim Breitmeyer (70 yo)

5.4yrs

在職期間

US$1,623,074

報酬

Dr. James B. Breitmeyer, also known as Jim, M.D., Ph D., served as Director of Otonomy, Inc. since June 20, 2018 until February 2023. He serves as Director of Rebalance Health, Inc. He serves as the Chief...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
James Breitmeyer	President	5.4yrs	US$1.62m	1.11% $ 23.3k
Richard Vincent	CFO & Treasurer	5.4yrs	US$847.91k	0.25% $ 5.2k
Rajesh Krishnan	Chief Technical & Scientific Officer	3.8yrs	データなし	0.074% $ 1.6k
Chase Leavitt	General Counsel & Secretary	3.6yrs	データなし	0.14% $ 3.0k
Pablo Urbaneja	Senior Vice President of Corporate Development	3.3yrs	データなし	データなし

3.8yrs

平均在職期間

55.5yo

平均年齢

経験豊富な経営陣: ONCTの経営陣は経験豊富であると考えられます ( 3.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
James Breitmeyer	President	5.4yrs	US$1.62m	1.11% $ 23.3k
Michael Carter	Independent Director	18.5yrs	US$59.80k	0.12% $ 2.6k
Daniel Kisner	Independent Director	5.4yrs	US$67.50k	0.017% $ 354.9
William LaRue	Independent Director	5.4yrs	US$67.00k	0.044% $ 928.6
David Hale	Independent Chairman of the Board	5.4yrs	US$103.82k	0.024% $ 506.8
Rosemary Mazanet	Independent Director	3.8yrs	US$61.32k	0.00017% $ 3.6
Thomas Kipps	Scientific Advisor	no data	データなし	データなし
Charles Theuer	Independent Director	5.4yrs	US$59.00k	0.025% $ 520.5
Robert Wills	Non-Independent Director	5.4yrs	US$55.00k	0.34% $ 7.1k
Marcela Maus	Cell Therapy Scientific Advisory Board Member	3yrs	データなし	データなし
Gunnar Kaufmann	Prostate Cancer & Cell Therapy Scientific Advisory Board Member	1.8yrs	US$941.21k	0.062% $ 1.3k
Michael Wang	Cell Therapy Scientific Advisory Board Member	3yrs	データなし	データなし

5.4yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: ONCTの取締役会は経験豊富であると考えられます ( 5.4年の平均在任期間)。

Oncternal Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Non-Independent Director recently bought US$59k worth of stock

Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science

Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Recent updates

Nasdaq Provides Notice on Oncternal's Common Stock Suspension on December 3, 2024

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Oncternal Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Oncternal Therapeutics, Inc. Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Price target decreased by 9.8% to US$27.67

Consensus estimates of losses per share improve by 10%

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Consensus EPS estimates fall by 12%

Oncternal Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates fall by 25%

Non-Independent Director recently bought US$59k worth of stock

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Oncternal Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science

Price target decreased by 8.5% to US$39.67

Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq’s Minimum Bid Price Requirement

Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Consensus revenue estimates increase by 13%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board

New major risk - Financial position

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates increase by 26%, EPS downgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oncternal Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

Oncternal Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Study of ROR1 Targeting Autologous CAR T, ONCT-808, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Consensus revenue estimates decrease by 26%, EPS upgraded

Consensus revenue estimates increase by 11%

Consensus revenue estimates fall by 30%

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Oncternal Therapeutics, Inc. Appoints Jill DeSimone to the Board of Directors

Oncternal Therapeutics, Inc. Announces the Resignation of Jinzhu Chen from the Board of Directors

Oncternal Therapeutics, Inc. Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib

Price target decreased to US$9.42

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.20 loss in 3Q 2021)

Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022

Oncternal Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma

FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oncternal Therapeutics, Inc Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL

Oncternal Therapeutics begins phase 3 study of zilovertamab

Oncternal Therapeutics: Selling For Under Cash Value

Oncternal Therapeutics, Inc. Submitted an Investigational New Drug Application (“IND”) for ONCT-808

Consensus forecasts updated

Price target decreased to US$9.42

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M

Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

High number of new directors

Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in Combination with Ibrutinib for Patients with MCL

Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study

Oncternal Therapeutics, Inc. Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress

マネジメント基準チェック /34